April 2026 continues to be a landmark month for biotechnology IPOs as Seaport Therapeutics and Hemab Therapeutics both outline their plans to go public. Each company is targeting a raise of approximately $180 million on the Nasdaq, adding to a surge in sector activity that suggests biotech is successfully navigating recent macroeconomic shifts in the U.S.
Seaport Therapeutics, led by former Karuna executives, is advancing a neuropsychiatric pipeline centered on GlyphAllo (SPT-300) for major depressive disorder. By utilizing its proprietary Glyph platform, the company aims to bypass first-pass liver metabolism through the lymphatic system, addressing long-standing bioavailability hurdles in brain-related therapies. Approximately $121 million of the IPO proceeds will fund SPT-300 through Phase IIb and into Phase III trials.
Simultaneously, Hemab Therapeutics is focusing its efforts on the blood coagulation space. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for rare bleeding disorders such as Factor VII deficiency. Hemab also plans to allocate $60 million toward HMB-002 for Von Willebrand Disease. These impending listings follow the massive $625 million IPO by Kailera Therapeutics earlier this month, signaling a robust appetite among investors for high-potential, late-stage biopharmaceutical assets.